Combination Chemotherapy in Patients With Newly Diagnosed BPDCN
Status:
Recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
Patients with suspected BPDCN and meeting eligibility criteria will be enrolled in the study.
First, BPDCN diagnosis will be confirmed by anatomic pathology (Dr Petrella T, Montreal) and
cytologic plus immunophenotyping analysis (Pr Garnache Ottou F, UMR1098 BESANCON). Patients
will then receive three 21 days cycles of a combination of chemotherapy
(Ida/Metho/L-asp/Dex), followed by an evaluation. Patients with complete response (CR) or
complete response with incomplete bone marrow recovery (CRi) will undergo an allo- or
auto-SCT and those who are not eligible to the transplantation will have successive 28 days
cycles of chemotherapy (Metho/L-asp/Dex). Patients who did not respond to the treatment will
be treated by physicians. All patients will be followed for 24 months.
Phase:
Phase 2
Details
Lead Sponsor:
Centre Hospitalier Universitaire de Besancon
Collaborators:
Centre Henri Becquerel Centre Hospitalier Universitaire Dijon Inserm CIC1431, CHU Besancon Maisonneuve-Rosemont Hospital UMR1098, EFS BFC, BESANCON